Association of udp-glucuronosyltransferase 1A9 (UGT1A9) gene polymorphism with kidney allograft function

Annals of Transplantation

Volumn 16, Issue 4, 2011, Pages 69-73

  Pazik, Joanna ^a   OŁdak, Monika ^a   Dabrowski, Marcin ^a   Lewandowski, Zbigniew ^a   Sitarek, Elzbieta ^a   Podgórska, Marta ^a   Wazna, Ewa ^a   PŁoski, RafaŁ ^a   Szmidt, Jacek ^a   Chmura, Andrzej ^a   Durlik, Magdalena ^a   Malejczyk, Jacek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Kidney allograft function; MMF therapy; UDP glucuronosyltransferases

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A9; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ALLELE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DNA ISOLATION; DNA POLYMORPHISM; DNA SEQUENCE; ENGRAFTMENT; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PROTEINURIA; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84855503236     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.882221     Document Type: Article

References (10)

1. Picard N, Ratanasavanh D, Prémaud A et al: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos, 2005; 33(1): 139-46
2. Girard H, Court MH, Bernard O et al: Identification of common polymorphisms in the promoter of theUGT1A9 gene: Evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics, 2004, 14: 501-15
3. Lévesque E, Delage R, Benoit-Biancamano MO et al: The impact of UGT1A8, UGT1A9, and UGT2B7 geneticpolymorphisms on the pharmacokinetic profile of mycophenolic acid aftera single oral dose in healthy volunteers. Clin Pharmacol Ther, 2007; 81: 392-400
4. van Schaik RH, van Agteren M, de Fijter JW et al: UGT1A9-275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther, 2009; 86(3): 319-27
5. Skórka A, Bednarczuk T, Bar-Andziak E et al: Lymphoid tyrosine phosphatase (PTPN22/LYP) variant and Graves' disease in a Polish population: association and gene dose-dependent correlation with age of onset. Clin Endocrinol (Oxf), 2005; 62(6): 679-82
6. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 1988; (16): 1215
7. Burchell B: Genetic variation of human UDP-glucuronosyltransferase: implications in disease and drug glucuronidation. Am J Pharmacogenomics, 2003; 3(1): 37-52
8. Shipkova M, Wieland E, Schütz E et al: The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc, 2001; 33(1-2): 1080-81
9. Schütz E, Shipkova M, Armstrong VW et al: Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem, 1999; 45(3): 419-22
10. Shipkova M, Armstrong VW, Oellerich M, Wieland E: Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol, 2005; 1(3): 505-26